Goldman Sachs has downgraded to a "sell" Canada Goose, a Canadian luxury outerwear maker with a market capitalization of just over $1 billion. As reasons for the move the investment bank cited high competition, weak sales in the luxury market, and slowing revenue growth. The same day, Canada Goose stock hit a one-month low in the U.S.

Goldman Sachs downgrades Canada Goose to a ‘sell’

Shares of GeoVax Labs, a biotechnology company developing a monkeypox treatment, soared more than 50% early on Monday, August 19. The jump came after disappointing study results for another monkeypox treatment developed by SIGA Technologies. In addition, last week the World Health Organization (WHO) declared a public health emergency due to the monkeypox outbreak in Africa, boosting the stocks of vaccine and drug makers  for several days in a row.

Evgenia Vatamanyuk

Writes about:

NVIDIA Corporation

Apple Inc.

Tesla, Inc.

Articles: 2

Goldman Sachs downgrades Canada Goose to a ‘sell’

Shares of monkeypox treatment maker GeoVax surge 50% amid news flow